CATALYST PHARMACEUTICALS, INC. (CPRX) Stock Profile — Insider Trades & Financials

Revenue$152.6M

Net Income$52.7M

EPS$1.68

Market Cap$3.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Patrick J. McEnany

CEO & Executive Director

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.

Employees: 176
Headquarters: CORAL GABLES, FL, United States
Website: www.catalystpharma.com

⚡

Core Efficiency

ROE?

5.52%

ROA?

4.77%

D/E Ratio?

0.16

Op. Margin?

40.52%

📊

Profitability Ratios

Net Margin?

34.53%

Loading company sections...

CATALYST PHARMACEUTICALS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness